What Researchers Did
The researchers tested albuterol inhalers inside a hyperbaric chamber at pressures from 1 ATA to 3 ATA to see how much medicine each puff released and how big and how many the aerosol particles were.
What They Found
This laboratory study of albuterol metered dose inhalers (MDIs) found that the amount released per puff and the aerosol particles emitted varied by canister type when the inhalers were used at pressures up to 3 ATA (66 fsw). Weight change per actuation was 13 +/- 1% less for CFC inhalers and 12 +/- 1% less for long canister HFA inhalers at 3 ATA than at 1 ATA, while short canister HFA inhalers showed no significant change. The geometric mean diameter of nanoparticles from the CFC and short canister HFA inhalers fell from 50 nm at 0 fsw to 32 nm at 66 fsw, but long canister HFA particle sizes were not affected. The number of nanometer size particles delivered at 66 fsw was 4-7% of that at 0 fsw for CFC and long canister HFA inhalers, and 26% for short canister inhalers.
What This Means for Canadian Patients
The abstract measured inhaler output in a chamber and did not test patients, so it does not report how well albuterol works for anyone at pressure. It shows that inhaler output changes with pressure and differs by canister type. Anyone who uses an inhaler and is thinking about hyperbaric exposure should ask their care team about it, since the abstract does not give guidance on use.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The abstract describes only measurements of inhaler output in a chamber, with no patients or clinical outcomes reported, so it cannot show whether the changes affect how well the medicine works.